News
Article
Author(s):
Verana Health’s newly launched Qdata Cataract offers a comprehensive dataset to improve outcomes, reduce complications and enhance IOL technology.
(Image credit: ©VirtualVista/AdobeStock)
A new dataset on cataract surgery outcomes was recently launched by Verana Health. Derived from more than 9 million cataract surgery patients, Qdata Cataract offers a comprehensive dataset with an average of nearly 4 years patient follow-up, shining insight into patient demographics, clinical characteristics, and treatment pathways aimed to support drug and treatment development.1
Cataracts are the leading cause of vision impairment, causing the eye’s lens to slowly and progressively become clouded over time. Nearly 3 million cataract surgeries are performed in the United States every year – one of the most common and successful medical procedures.
“While cataract surgery is highly successful, real-world insights into surgical outcomes, lens selection, and patient experiences remain fragmented,” Sujay Jadhav, chief executive officer of Verana Health, said in a press release. “Qdata Cataracts delivers a new level of clarity, equipping life sciences companies with high-quality evidence to advance clinical research, improve outcomes, reduce complications, and enhance intraocular lens technology.”
The American Academy of Ophthalmology IRIS Registry, the world’s largest specialty society clinical data registry, powers Qdata Cataract through its exclusive electronic health record data. The dataset includes key variables such as: visual acuity, intraocular pressure reading, and intraocular lens brand and model; as well as providing clinical, real-world evidence informing clinical development, health economics and outcomes research (HEOR), and commercialization strategies.
This comprehensive data allows for cohort identification, patient stratification, and real-world outcomes analysis. These insights will help to allow for the evaluation of post-surgical outcomes, patient responses to different intraocular lens models, as well as treatment effectiveness.
Additionally, Qdata Cataracts offers the support for a range of applications – identifying practices treating cataract patients for clinical trial optimization, assessing treatment patterns and patient outcomes for HEOR initiatives, and refunding market insights for commercialization efforts.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.